Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
From somatostatin to octreotide LAR: evolution of a somatostatin analogue
Current Medical Research and Opinion, 11/05/09
Anthony L et al. – Octreotide is a potent synthetic somatostatin analogue that has become the mainstay of medical therapy for tumor control in neuroendocrine disorders such as acromegaly and GEP–NETs. The development of octreotide LAR offered a further advancement; less frequent dosing provided valuable benefits in quality of life to patients, with equivalent efficacy and tolerability. Moreover, recent results from the PROMID study have confirmed the antiproliferative effect of octreotide LAR in patients with well–differentiated metastatic GEP–NETs of the midgut. New therapeutic uses of octreotide are currently under investigation in a variety of clinical settings.
Related Articles
Continuous 5-fluorouracil infusion plus long acting Octreotide in advanced well differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte Oncology Network.
BMC Cancer, 11/09/09
Relevance Score: 87%
High-dose Octreotide Acetate for Management of Gastroenteropancreatic Neuroendocrine Tumors
Anticancer Research, 11/11/09
Relevance Score: 85%
Treatment of Malignant Enterovesical Fistula with Octreotide
Journal of Palliative Medicine, 10/12/09
Relevance Score: 85%
The Efficacy of Octreotide LAR as Firstline Therapy for Patients with Newly Diagnosed Acromegaly is Independent of Tumor Extension: Predictive Factors of Tumor and Biochemical Response
Hormone and Metabolic Research, 10/06/09
Relevance Score: 85%
Resolution of chyloperitoneum in a preterm with octreotide, diet and cessation of dialysis
Pediatric Nephrology, 11/16/09
Relevance Score: 84%
Today in Chemotherapy/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Valproic acid restores ERalpha and antiestrogen sensitivity to ERalpha-negative breast cancer cells
Molecular and Cellular Endocrinology, 11/25/09
N2 Disease in Patients With Head and Neck Squamous Cell Cancer Treated With Chemoradiotherapy
Archives of Otolaryngology, 11/25/09
Salvage treatment with upfront melphalan 100 mg/m2 and consolidation with novel drugs for fulminant progression of multiple myeloma
Annals of Hematology, 11/24/09
Sponsor
Article Search
Sponsor


See Latest Articles


